Sotera Health Sees 10% Q1 Revenue Growth, Names Alton Shader CEO
Q1 2026 net revenues rose 10.0% (6.5% constant currency), driving net income of $27 million versus a $13 million loss and adjusted EBITDA growth of 10.5% with adjusted EPS up 29% to $0.18. Sotera Health reaffirmed 2026 guidance for 5.0%-6.5% revenue growth and 5.5%-7.0% EBITDA growth, naming Alton Shader as CEO May 26.
1. Q1 2026 Financial Highlights
Sotera Health reported net revenues up 10.0% year-over-year (6.5% constant currency) in Q1 2026, delivering net income of $27 million versus a $13 million loss in Q1 2025, adjusted EBITDA growth of 10.5% and adjusted EPS of $0.18, a 29% increase.
2. Business Segment Performance
Sterigenics achieved net revenues of $186 million, up 6.1% constant currency, with segment income rising 9.6% to $96 million; Nordion posted $42 million in revenues, up 25.8% constant currency, and segment income of $24 million, up 36.1%; Nelson Labs saw revenues of $52 million, down 3.8% constant currency, and segment income of $15 million, down 11.5%.
3. Reaffirmed 2026 Guidance and Financial Position
The company reaffirmed full-year 2026 outlook for net revenues of $1.233–$1.251 billion (5.0%–6.5% constant currency growth) and adjusted EBITDA of $632–$641 million (5.5%–7.0% constant currency growth), with projected adjusted EPS of $0.93–$1.01, capex of $175–$225 million; net leverage was 3.2x with over $900 million in available liquidity.
4. Planned CEO Transition
Alton Shader, CEO of Viant Medical, will assume the role of Sotera Health CEO on May 26, succeeding Michael B. Petras, Jr., who will become Executive Chairman and remain active in investor relations and strategic initiatives; Shader brings over 20 years of medical industry leadership and a track record of global growth and operational excellence.